Family · Pharmaceutical analytical standards
Carvedilol
A non-selective beta blocker that also blocks alpha-1 receptors, widening the blood vessels: patented in 1978 and approved in the United States in 1995, it is used for hypertension and heart failure. It also has antioxidant properties. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Until the 1990s beta blockers were considered contraindicated in heart failure: in 1997 carvedilol became the first beta blocker approved in the United States for precisely this condition.
No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
